Mein Warenkorb

LGR5

LGR5 Molekülinformation

Englischer NameLeucine-rich repeat-containing G-protein coupled receptor 5Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2Target-AliasFEX,G Protein-Coupled Receptor 49,GRP49,HG38,G-protein coupled receptor HG38,GPR49,GPR67,G-protein coupled receptor 49,Leucine-rich repeat-containing G-protein coupled receptor 5,LGR5,Leucine Rich Repeat Containing G Protein-Coupled Receptor 5,G-Protein Coupled Receptor 67,Orphan G Protein-Coupled Receptor HG38
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameLeucine-rich repeat-containing G-protein coupled receptor 5
Target-AliasFEX,G Protein-Coupled Receptor 49,GRP49,HG38,G-protein coupled receptor HG38,GPR49,GPR67,G-protein coupled receptor 49,Leucine-rich repeat-containing G-protein coupled receptor 5,LGR5,Leucine Rich Repeat Containing G Protein-Coupled Receptor 5,G-Protein Coupled Receptor 67,Orphan G Protein-Coupled Receptor HG38
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

LGR5 Produktliste

  • Attribut

    Protein (4)Cell (1)

  • Produktbibliothek

    Online (5)

  • Spezies

    Human (4)Cynomolgus (1)

  • Etikett

    His Tag (2)Fc Tag (1)His Tag & Avi Tag (1)- (1)

  • Marker

    Unconjugated (3)Biotin-labeled (1)- (1)

LGR5 Molekülhintergrund

LGR5 (also known as GPR49) is a seven-transmembrane protein of the class A Rhodopsin-like family of GPCRs. LGR5 and LGR4 bind the R-spondins with high affinity and mediate the potentiation of Wnt/β-catenin signaling by enhancing Wnt-induced LRP6 phosphorylation. The LGR5/RSPO complex could promote Wnt signalling via the neutralization of two transmembrane E3 ligases, RNF43 and ZNRF3.

LGR5 Molekülalias

LGR5, GPR49, GPR67, G-protein coupled receptor 49, G-protein coupled receptor 67, G-protein coupled receptor HG38, Leucine-rich repeat-containing G-protein coupled receptor 5

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
PetosemtamabMCLA-158Phase 2 ClinicalMerus NvCarcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
CNA-3103CNA-3103Phase 2 ClinicalCarina Biotech Pty LtdColorectal Neoplasms
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns